Employers › BioMarin Pharmaceutical
Recordkeeping fees per participant · Biomarin Pharmaceutical Inc. Retirement Savings Plan · plan year 2024
$2.54
Higher than 3% of the 1,697 plans $250M to 1B that report it.
= $8,300 / 3,270
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251204130915NAL0001179187001, received 2025-12-04
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251204130915NAL0001179187001, received 2025-12-04
Percentiles compare this plan with the Schedule H plans $250M to 1B in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-12-04.
Administrative expenses excluding investment management, per participant
$2.54
Higher than 2% of the 2,324 plans $250M to 1B that report it.
= $8,300 / 3,270
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251204130915NAL0001179187001, received 2025-12-04
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251204130915NAL0001179187001, received 2025-12-04
Administrative expenses per participant
$16.76
Higher than 6% of the 2,405 plans $250M to 1B that report it.
= $54,811 / 3,270
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251204130915NAL0001179187001, received 2025-12-04
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251204130915NAL0001179187001, received 2025-12-04
Administrative expenses as a share of assets
0.008%
Higher than 4% of the 2,407 plans $250M to 1B that report it.
= $54,811 / $715,040,838
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251204130915NAL0001179187001, received 2025-12-04
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251204130915NAL0001179187001, received 2025-12-04
Employer contributions per participant
$7,730
Higher than 88% of the 2,457 plans $250M to 1B that report it.
= $25,276,297 / 3,270
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251204130915NAL0001179187001, received 2025-12-04
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251204130915NAL0001179187001, received 2025-12-04
Employer share of total contributions
36.1%
Higher than 66% of the 2,459 plans $250M to 1B that report it.
= $25,276,297 / $69,962,423
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251204130915NAL0001179187001, received 2025-12-04
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251204130915NAL0001179187001, received 2025-12-04
Employer match
“The Company pays the direct expenses of the 401(k) Plan and matches 100% of each participating employee’s eligible contributions, up to a maximum of the lesser of 6% of the employee’s annual compensation or the annual statutory contribution limit.”
Form 10-K filed 2026-02-26, for the year ended 2025-12-31 · benefits note, 10-K benefits note · source document
Vesting
“The Company’s matching contribution vests immediately and was approximately $33.4 million, $34.4 million and $32.7 million for the years ended December 31, 2025, 2024 and 2023, respectively.”
Form 10-K filed 2026-02-26, for the year ended 2025-12-31 · benefits note, 10-K benefits note · source document
Terms quoted from the filing for the year ended 2025-12-31. Figures cover plan year 2024. The plan document governs.
2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2R participant brokerage window · 2S pre-approved plan document · 2T default investment (QDIA) · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20251204130915NAL0001179187001, received 2025-12-04
| Field | Value | Source |
|---|---|---|
| Plan sponsor | BIOMARIN PHARMACEUTICAL INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Plan name | BIOMARIN PHARMACEUTICAL INC. RETIREMENT SAVINGS PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Sponsor EIN / plan number | 68-0397820 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Sponsor location | NOVATO, CA | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Filing received | 2025-12-04 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Amended filing | yes | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Participants, beginning of year | 3,448 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Active participants | 1,939 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Participants, end of year | 3,321 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Participants with an account balance | 3,270 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Total assets, beginning of year | $616,847,325 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Total assets, end of year | $715,040,838 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Net assets, end of year | $715,040,838 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Total income | $167,766,467 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Net income | $98,193,513 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Employer contributions | $25,276,297 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Participant contributions | $38,890,702 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Other contributions (incl. rollovers) | $5,795,424 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Total contributions | $69,962,423 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Benefit payments | $69,418,876 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Total expenses (incl. benefit payments) | $69,572,954 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Total administrative expenses | $54,811 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Recordkeeping fees | $8,300 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Investment advisory and management fees | $46,511 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Administrative expenses excluding investment management | $8,300 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Held in common/collective trusts | $310,598,804 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Held in mutual funds | $342,946,439 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20251204130915NAL0001179187001, received 2025-12-04 |
| Independent auditor | BAKER TILLY US, LLP | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20251204130915NAL0001179187001, received 2025-12-04 |
Position = column in the DOL layout for form year 2024. Filing 20251204130915NAL0001179187001, received 2025-12-04.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| DYNAMIC WEALTH ADVISORS | NONE | 26 Investment advisory (participants); 50 Direct payment from the plan | $11,913 | no |
| SCHWAB RETIREMENT PLAN SERVICES,INCrecordkeeper | NONE | 15 Recordkeeping and information management; 50 Direct payment from the plan; 64 Recordkeeping fees | $8,250 | no |
| CREATIVE PLANNING LLC | NONE | 26 Investment advisory (participants); 50 Direct payment from the plan | $8,031 | no |
| ABOUND WEALTH MANAGEMENT LLC | NONE | 26 Investment advisory (participants); 50 Direct payment from the plan | $7,317 | no |
| SIGNATURE ESTATE & INVESTMENT | NONE | 26 Investment advisory (participants); 50 Direct payment from the plan | $5,225 | no |
| CHARLES SCHWAB & CO., INC | NONE | 33 Securities brokerage; 50 Direct payment from the plan; 62 Float revenue; 71 Securities brokerage commissions and fees; 59 Shareholder servicing fees | $1,763 | yes |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20251204130915NAL0001179187001, received 2025-12-04.
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $616,847,325 | $715,040,838 | 15.9% |
| Participants with a balance | 3,377 | 3,270 | -3.2% |
| Administrative expenses | $50,285 | $54,811 | 9.0% |
| Recordkeeping fees per participant | $2.04 | $2.54 | 24.2% |
| Employer contributions | $24,916,499 | $25,276,297 | 1.4% |
Prior filing 20241011171830NAL0045269330001, received 2024-10-11; the plan years are contiguous.
Sponsor name as filed: BIOMARIN PHARMACEUTICAL INC.; SEC registrant: BIOMARIN PHARMACEUTICAL INC (CIK 1048477, matched by EIN; display name from the Form 10-K cover).